Wastewater treatment

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

Retrieved on: 
Friday, April 26, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, School, University, Global Oncology, Cancer, Wastewater treatment, University of Pennsylvania, Pharmacovigilance, Incyte, Hematology, GSK plc, Drug, Partnership, MPM, Senior, Patient, Therapy, Head

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.
  • “On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare into the leading precision oncology company that it is today.
  • "I look forward to the ongoing advancement of Repare’s pipeline and its continued progress as a leading precision oncology company."
  • Dr. Stein also previously served on the board of directors of Kura Oncology, Inc. from 2017 until May 2023.

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
Tuesday, April 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

Fluence Secures Industrial Wastewater and Biogas Contracts Worth $3.7M and Gains Traction in North America Municipal Water & Wastewater With $3.3M in Bookings

Retrieved on: 
Thursday, March 14, 2024
UV, GM, Water, Environment, Public health, Wastewater treatment, Amyl nitrite, ASX, Pro-Life Action League, Buddleja salviifolia, BNR, Traction, FLC, Municipality, Disinfectant, Sewage treatment

MINNEAPOLIS, March 14, 2024 /PRNewswire-PRWeb/ -- Fluence Corporation Limited (ASX: FLC; the "Company") is pleased to announce it has been awarded two Industrial Wastewater and Biogas contracts with a total value of $3.7M. In addition, Fluence is gaining traction in North America with $3.3M of Municipal Water and Wastewater bookings in the first two months of 2024, eclipsing the region's total municipal sales for all of 2023.

Key Points: 
  • In addition, Fluence is gaining traction in North America with $3.3M of Municipal Water and Wastewater bookings in the first two months of 2024, eclipsing the region's total municipal sales for all of 2023.
  • "These wins open the door for more BNR (biological nutrient removal) projects in Colorado, Indiana, and other states across the country."
  • In addition, a major food processing company in northern Italy has purchased a new pre-treatment process from Fluence for $1.4M.
  • Fluence's Municipal Water & Wastewater group has secured several contracts in North America, with a total value of $3.3M.

ChemoMouthpiece, LLC. Announces the Awarding of the 510(k) Marketing Clearance by the FDA for their Oncology Supportive Care Device and Recent Closing of their Private Placement Round

Retrieved on: 
Thursday, February 22, 2024
Vasoconstriction, Incidence, Marketing, ONS, Oncology Nursing Society, Multimedia, ASCO, FDA, News, Pain, Hodgkin lymphoma, Cryotherapy, Nausea, Manuscript, Risk, Mouth, Society, Wastewater treatment, Patient, Chemotherapy, Clinical trial, Lymphoma, Mucositis, Dentistry

announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.

Key Points: 
  • announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.
  • has just closed on their Private Placement Round of $10 million in upfront capital with a full commitment for the second tranche of additional funds in excess of $10 million.
  • "Chemo Mouthpiece™ is fully stocked, as we will begin shipping across the US within the next quarter now that we have FDA Marketing Clearance.
  • ChemoMouthpiece, LLC is a privately held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients.

Tennessee Oncology Launches Rural Telehealth Program to Bridge Digital Divide for Middle Tennessee Cancer Patients

Retrieved on: 
Tuesday, February 20, 2024
Breast cancer, Palliative care, COVID-19, Caregiver, Survivor, Psychology, Community engagement, Physician, Quality of life, Extension, Breast, Health care, Wastewater treatment, University, Counselor, Evaluation, CAB, Patient, Senior counsel, Oncology, NEST, Health equity, Community-based participatory research, Travel, Cancer, Prostate cancer, Nursing

To kick off the program, Tennessee Oncology is recruiting Middle Tennessee cancer patients, caregivers, survivors, and patient advocates to participate in the program's design as part of Community Advisory Boards (CABs).

Key Points: 
  • To kick off the program, Tennessee Oncology is recruiting Middle Tennessee cancer patients, caregivers, survivors, and patient advocates to participate in the program's design as part of Community Advisory Boards (CABs).
  • During the Covid-19 pandemic when Tennessee Oncology rapidly deployed telehealth services, patient participation in palliative care, psychology, and integrative oncology grew.
  • In 2022, only 1.5 percent of breast cancer patients and 2.7 percent of prostate cancer patients accessed palliative care in rural and underserved Tennessee counties.
  • "NEST was born from what we learned using telehealth to connect our patients with cancer care services during the pandemic," said Natalie Dickson, MD, President and Chief Strategy Officer, Tennessee Oncology.

New Guidance Published in The Lancet Recommends Early Intervention and Use of BIS to Reduce Impact of Arm Lymphedema on Breast Cancer Patients

Retrieved on: 
Thursday, February 15, 2024
Breast cancer, American Cancer Society, Survivor, BIS, Education, MD, FDA, Lymphedema, Quality of life, MBA, Manuscript, Risk, Wastewater treatment, Lancet, Health, Patient, Melanoma

CARLSBAD, Calif., Feb. 15, 2024 /PRNewswire/ -- ImpediMed, a pioneer in the field of medical technology, announced a significant advancement in the fight against breast cancer-related lymphedema, a common but often overlooked condition affecting breast cancer survivors. Leading medical journal eClinicalMedicine, part of The Lancet Discovery Science, recently published new clinical guidance advocating for early detection and prevention strategies, underscoring the validity and efficacy of ImpediMed's innovative approach.

Key Points: 
  • Leading medical journal eClinicalMedicine, part of The Lancet Discovery Science, recently published new clinical guidance advocating for early detection and prevention strategies, underscoring the validity and efficacy of ImpediMed's innovative approach.
  • At the center of these recommendations is bioimpedance spectroscopy (BIS), a cutting-edge technology pioneered by ImpediMed, designed to help detect lymphedema in its early stages before it becomes a significant problem.
  • According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk.
  • The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema.

Fuel Tech Publishes White Paper on Positive Effects of Its Dissolved Gas Infusion Technology in an Aquaculture Setting

Retrieved on: 
Tuesday, February 6, 2024
Other Energy, Utilities, Oil, Gas, Nuclear, Coal, Alternative Energy, Energy, Technology, Other Manufacturing, Engineering, Other Technology, Manufacturing, Biophysical environment, Research, Survival, Growth, Oxygen, Biomass, Royal, Water, Fuel, ASCE, DGI, Society, Wastewater treatment, Doctor of Philosophy, Shrimp, Aquaculture

Dissolved Gas Infusion (DGI®) Technology for the Royal Caridea Aquaculture Raceway , suggests that the use of DGI® to reliably dose and maintain dissolved oxygen levels can dramatically increase total production compared with traditional aeration methods.

Key Points: 
  • Dissolved Gas Infusion (DGI®) Technology for the Royal Caridea Aquaculture Raceway , suggests that the use of DGI® to reliably dose and maintain dissolved oxygen levels can dramatically increase total production compared with traditional aeration methods.
  • Shrimp farm technology provider Royal Caridea worked closely with Fuel Tech on a trial to determine the effects of growing Pacific whiteleg shrimp (Litopenaeus Vannamei) in a raceway system using the Company’s patented DGI® gas infusion system.
  • In the second growth cycle, Fuel Tech’s DGI® technology was used to provide DO concentrations at 150% of atmospheric saturation.
  • The validation testing white paper showed that DGI delivers greater than 99% transfer of oxygen when applied to a treated body of water.

Equinix Fully Allocates $4.9 Billion of Green Bond Proceeds

Retrieved on: 
Wednesday, December 20, 2023
SBT, OK, PUE, PPA, Biodiversity, IBX, Transport, Wind, GHG, Sustainability, Professional, Pact, Electricity, Climate, Renewable energy, International Capital Market Association, GLP, Wastewater treatment, Building, Carbon, CDP, Global warming potential, GBP, EQIX, Waste management, Environment

Since 2020, six bond offerings have been issued, and as of the end of June 2023, all bonds have been fully allocated.

Key Points: 
  • Since 2020, six bond offerings have been issued, and as of the end of June 2023, all bonds have been fully allocated.
  • Equinix has developed a Green Finance Framework based on the Green Bond Principles and Green Loan Principles, a set of guidelines that promote transparency and integrity in, and advance the standardization of, green debt disclosures.
  • In line with the International Capital Market Association's Green Bond Principles (GBP) 2018 and the Loan Syndications and Trading Association's Green Loan Principles (GLP) 2020, Equinix is allocating 100% of the Green Financing net proceeds to a portfolio of Eligible Green Projects which showcase how Equinix is building and operating sustainably, including Green Buildings; Renewable Energy; Energy Efficiency; Sustainable Water and Wastewater Management; Waste Management; and Clean Transportation.
  • Equinix publishes its Green Bond Allocation and Impact Reports annually to provide transparency on progress.

Global Calcium Nitrate Strategic Market Report 2023-2030: Widespread Opportunities in Wastewater Treatment Accelerate Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, December 1, 2023
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Wastewater, Fertilizer, Growth, Calcium nitrate, Wastewater treatment, Video game

The "Calcium Nitrate - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Calcium Nitrate - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • One of the key drivers of its market expansion is the increasing use of calcium nitrate in wastewater treatment processes.
  • The competitive scenario in the calcium nitrate market involves key global brands, with varying degrees of market presence, from strong to niche players.
  • The world calcium nitrate market reflects diverse application areas, with significant percentages of revenues attributed to fertilizers, wastewater treatment, explosives, concrete manufacturing, and other applications.

NCCN Summit Navigates Solutions for Financial and Other Cancer-Related Hardships

Retrieved on: 
Tuesday, December 5, 2023
Disease, Health equity, Cancer Support Community, Senior, DNP, Life, Patient, UAB, CMS, Partnership, Doctor of Philosophy, Mental health, Quality of life, Engagement, Toxicity, National Comprehensive Cancer Network, Mortality, MSS, MSCE, Risk, CSSBB, Health, FCPP, DEI, Estate (law), Durrow healthcare consultancy, Public policy, FACP, NCCN, University of Pennsylvania, Imerman Angels, Social conditioning, ACCC, Leadership Council, Patient navigators, University, Medicare, Diversity, Education, Chief innovation officer, Associate, LCSW, Policy, MMM, Navigation, RN, Breast cancer, LSW, Inclusion, Refugee, Survival, Social work, Wastewater treatment, Pharmaceutical industry, Medical device, Hospital, Management, Nursing, Cancer, MSW, Medicine, MD

PLYMOUTH MEETING, Pa., Dec. 5, 2023 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted a Patient Advocacy Summit to explore the role of navigation throughout the cancer process. A diverse group of subject matter experts addressed the impact patient navigation has on care and how to utilize navigators to reduce economic burdens and disparities in care. The speakers included patients and advocates, policymakers, health care providers, and health data analysts.

Key Points: 
  • Denlinger
    The summit featured a series of best practice presentations highlighting some of the tools available to assist in various areas of patient navigation.
  • Speakers identified significant financial hardships that can come with cancer care, which can contribute to logistical barriers or issues involving emotional well-being.
  • Navigating a patient through their healthcare coverage and preventing financial ruin from astronomical cancer care costs has grown more complex.
  • NCCN's annual Patient Advocacy Summit follows another recent Oncology Policy Summit where the organization unveiled recommendations for screening health-related social needs ( HRSN ) in cancer care.